[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332704-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332704-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nek2-is-a-potential-pan-cancer-biomarker-and-immunotherapy-target","NEK2 is a potential pan-cancer biomarker and immunotherapy target","","NEK2, a member of the NEKs family involved in cell mitosis, is linked to the development of multiple tumors, yet systematic pan-cancer evidence remains insufficient. This study assessed the prognostic value of NEK2 across 33 cancers using TCGA and GTEx, examining gene and protein expression, tumor microenvironment features, and drug sensitivity. Bioinformatics suggested oncogenic potential and in vitro work preliminarily validated cervical cancer relevance. Results indicate broad NEK2 overexpression, worse outcomes with NEK2 mutations, and associations with immune infiltration and immune checkpoint genes, supporting immunotherapy targeting potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nek2-is-a-potential-pan-cancer-biomarker-and-immunotherapy-target/332704/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nek2-is-a-potential-pan-cancer-biomarker-and-immunotherapy-target/332704.png","ImageObject",300,407,{"name":42,"@type":43},"Skyler","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study on NEK2 in cancer?","Question",{"text":63,"@type":64},"To evaluate the prognostic value and potential functional role of NEK2 across 33 cancers, focusing on pan-cancer relevance and immunotherapy potential.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were NEK2 associations analyzed in pan-cancers?",{"text":68,"@type":64},"The study used TCGA and GTEx to investigate NEK2 gene and protein expression, relationships with tumor microenvironment features, and drug sensitivity through multiple software and web platforms.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports NEK2 as a possible immunotherapy target?",{"text":72,"@type":64},"NEK2 is overexpressed in almost all tumors, its mutation correlates with poorer prognosis, and NEK2 expression correlates with immune features such as immune cell infiltration, immune checkpoint genes, TMB, and MSI.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332704,1790217054,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Research  \nNEK2 is a potential pan‑cancer biomarker and immunotherapy target  \nLanyue Zhang1 · Yang Li1 · Juexiao Deng1 · Wenxin Liao1 · Tingting Liu1 · Fujin Shen1  \nReceived: 29 August 2024 / Accepted: 4 November 2024  \n© The Author(s) 2024 OPEN  \nAbstract  \nBackground NEK2 is a member of the NEKs family and plays an important role in cell mitosis. Increasing evidence suggests that NEK2 is associated with the development of multiple tumors, but systematic studies of NEK2 in cancer are still lacking. Therefore, we evaluated the prognostic value of NEK2 in 33 cancers to elucidate the potential function of NEK2 in pan-cancers.  \nMethods We investigated the role of NEK2 in pan-cancers utilizing The Cancer Genome Atlas (TCGA) and the GenotypeTissue Expression (GTEx) database. Additionally, we analyzed the association between NEK2 gene expression across various cancers, protein expression, the tumor microenvironment (TME), and drug sensitivity using several software and web platforms.The potential oncogenic role of NEK2 was initially explored using bioinformatics methods. Furthermore, we conducted in vitro experiments to preliminarily validate the function of NEK2 in cervical cancer.  \nResults NEK2 is overexpressed in almost all tumors, and mutation of NEK2 are associated with a poorer tumor prognosis. In addition, the correlation between NEK2 and immune features such as immune cell infiltration, immune checkpoint genes, tumor mutational burden (TMB), Microsatellite instability(MSI) etc. suggest that NEK2 could potentially be applied in the immunotherapy of tumors.  \nConclusion NEK2 may be a potential pan-cancer biomarker and immunotherapeutic target for improving the efficacy of tumor therapy.  \nKeywords NEK2 · Pan-cancers · Diagnosis · Prognosis · Tumor immunity  \nAbbreviations  \nTCGA The cancer genome Atlas GTEx Genotype-tissue expression HPA The human protein atlasv TMB Tumor mutational burden TME Tumor microenvironment MSI Microsatellite instability OS Overall survival  \nDSS Disease specific survival  \nLanyue Zhang, Yang Li and Juexiao Deng have authors contributed equally to this work.  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-024-](https://doi.org/10.1007/s12672-024-)[ ](https://doi.org/10.1007/s12672-024-)[01519-7](01519-7.)[.](01519-7.)  \n* Fujin Shen, [sfj296@163.com |](sfj296@163.com |1Department of Obstetrics and Gynecology)[1](sfj296@163.com |1Department of Obstetrics and Gynecology)[Department of Obstetrics and Gynecology](sfj296@163.com |1Department of Obstetrics and Gynecology), Renmin Hospital of Wuhan University, 239 Jiefang Road, Wuchang District, Wuhan 430060, Hubei, China.  \nDiscover Oncology  \n(2024) 15:626  \n| [https://doi.org/10.1007/s12672-024-01519-7](https://doi.org/10.1007/s12672-024-01519-7)  \nPFI Progression-free interval DFI Disease-free interval KM Kaplan–Meier  \nGO Gene ontology  \nKEGG Kyoto encyclopedia of genes and genomes GSEA Gene set enrichment analysis  \nPPI Protein–protein interaction NIMA Never In mitosis gene AACC Adrenocortical carcinoma BLCA Bladder urothelial carcinoma BRCA Breast invasive carcinoma  \nCESC Cervical squamous cell carcinoma and endocervical adenocarcinoma CHOL Cholangiocarcinoma  \nCOAD Colon adenocarcinoma  \nDLBC Lymphoid neoplasm diffuse large B-cell Lymphoma ESCA Esophageal carcinoma  \nGBM Glioblastoma multiforme  \nHNSC Head and neck squamous cell carcinoma KICH Kidney chromophobe  \nKIRC Kidney renal clear cell carcinoma KIRP Kidney renal papillary cell carcinoma  \nLAML Acute myeloid leukemia LGG Brain lower grade glioma LIHC Liver hepatocellular carcinoma LUAD Lung adenocarcinoma  \nLUSC Lung squamous cell carcinoma MESO Mesothelioma  \nOV Ovarian serous cystadenocarcinoma PAAD Pancreatic adenocarcinoma  \nPCPG Pheochromocytoma and Paraganglioma PRAD Prostate adenocarcinoma  \nREAD Rectum adenocarcinoma  \nSARC Sarcoma  \nSKCM Skin cutaneous melanoma STAD Stomach adenocarcinoma TGCT Testicular ","cbCaikU9wcZAijHQ","https://ap.wps.com/l/cbCaikU9wcZAijHQ","pdf",5633550,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Cancer burden and immunotherapy context\n## Public databases and biomarker importance","[{\"question\":\"What is the main purpose of the study on NEK2 in cancer?\",\"answer\":\"To evaluate the prognostic value and potential functional role of NEK2 across 33 cancers, focusing on pan-cancer relevance and immunotherapy potential.\"},{\"question\":\"How were NEK2 associations analyzed in pan-cancers?\",\"answer\":\"The study used TCGA and GTEx to investigate NEK2 gene and protein expression, relationships with tumor microenvironment features, and drug sensitivity through multiple software and web platforms.\"},{\"question\":\"What evidence supports NEK2 as a possible immunotherapy target?\",\"answer\":\"NEK2 is overexpressed in almost all tumors, its mutation correlates with poorer prognosis, and NEK2 expression correlates with immune features such as immune cell infiltration, immune checkpoint genes, TMB, and MSI.\"}]","NEK2 is a potential pan-cancer biomarker and immunotherapy target | PDF",1789999135,45]